SOPHIA GENETICS SA (SOPH)
CH1125843347 - Common Stock
ChartMill assigns a Buy % Consensus number of 84% to SOPH. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.12. This target is 40.05% above the current price.
SOPH was analyzed by 11 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about SOPH.
In the previous month the buy percentage consensus was at a similar level.
SOPH was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-08-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-06-27 | Guggenheim | Initiate | Buy |
| 2024-03-06 | BTIG | Maintains | Buy -> Buy |
| 2024-03-06 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-01-12 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-11-29 | RBC Capital | Initiate | Outperform |
| 2023-05-10 | Credit Suisse | Maintains | Neutral |
| 2023-05-10 | Morgan Stanley | Maintains | Overweight |
| 2023-03-08 | Morgan Stanley | Maintains | Overweight |
| 2023-01-03 | BTIG | Initiate | Buy |
| 2022-11-23 | Credit Suisse | Initiate | Neutral |
| 2022-11-09 | Morgan Stanley | Maintains | Overweight |
| 2022-08-10 | Morgan Stanley | Maintains | Overweight |
| 2022-05-11 | Morgan Stanley | Maintains | Overweight |
| 2022-02-15 | Morgan Stanley | Maintains | Overweight |
| 2021-08-17 | Cowen & Co. | Initiate | Outperform |
| 2021-08-17 | JP Morgan | Initiate | Overweight |
| 2021-08-17 | Credit Suisse | Initiate | Outperform |
| 2021-08-17 | Morgan Stanley | Initiate | Overweight |